| pubmed-article:7582985 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7582985 | lifeskim:mentions | umls-concept:C0040018 | lld:lifeskim |
| pubmed-article:7582985 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:7582985 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:7582985 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:7582985 | pubmed:dateCreated | 1995-12-18 | lld:pubmed |
| pubmed-article:7582985 | pubmed:abstractText | A series of 3-(3-guanidinopropyl)-azetidin-2-one derivatives was prepared and evaluated as inhibitors of cleavage of synthetic substrates in vitro by the serine proteases thrombin, trypsin and plasmin. The N-unsubstituted, 4-phenethyl derivative 9a demonstrated weak inhibition of these enzymes but acetylation of the beta-lactam N atom afforded 9b, an effective, time-dependent inhibitor of thrombin and a potent inhibitor of plasmin. Variation of the 4-position of the beta-lactam ring was examined in conjunction with different N-substituents to provide a series of potent, time-dependent inhibitors of thrombin. A C-4 substituent was essential for good inhibitory properties and, in general, polar C-4 substituents enhanced the selectivity of inhibition for thrombin compared to plasmin. A trans relationship between the C-4 and C-3 substituents was found to be superior to a cis disposition whilst homologation of the guanidinopropyl side chain to that of a guanidinobutyl moiety reduced activity. Several compounds were effective inhibitors of thrombin-induced clot formation in human plasma in vitro but activity in this assay did not correlate well with inhibition of thrombin-induced cleavage of a synthetic substrate, presumably a consequence of inherent chemical instability and degradation in plasma. | lld:pubmed |
| pubmed-article:7582985 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7582985 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7582985 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7582985 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7582985 | pubmed:issn | 0968-0896 | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:WrightJ JJJ | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:HaoW QWQ | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:MeanwellN ANA | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:TrehanA KAK | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:SeilerS MSM | lld:pubmed |
| pubmed-article:7582985 | pubmed:author | pubmed-author:FedericiM EME | lld:pubmed |
| pubmed-article:7582985 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7582985 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:7582985 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7582985 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7582985 | pubmed:pagination | 1123-43 | lld:pubmed |
| pubmed-article:7582985 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:meshHeading | pubmed-meshheading:7582985-... | lld:pubmed |
| pubmed-article:7582985 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7582985 | pubmed:articleTitle | Azetidin-2-one derivatives as inhibitors of thrombin. | lld:pubmed |
| pubmed-article:7582985 | pubmed:affiliation | Division of Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660, USA. | lld:pubmed |
| pubmed-article:7582985 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7582985 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7582985 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7582985 | lld:pubmed |
